首页> 外文期刊>The Lancet >Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.
【24h】

Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.

机译:中心对急性髓细胞白血病骨髓移植结局的影响。欧洲血液和骨髓移植小组急性白血病工作组。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: There is increasing pressure for the recognition and replication of good clinical practice. We undertook a study to assess the variability in outcome of allogeneic bone-marrow transplantation among major European centres. METHODS: We studied 13 centres, including 522 patients (aged 16-55 years), which had undertaken more than 30 bone-marrow transplantations between Jan 1, 1987, and Dec 31, 1995, for acute myeloid leukaemia in first complete remission. We undertook a (global) multivariate analysis of all factors known previously to influence outcome and a stratified analysis that initially defined, by multivariate analysis, significant variables in this study and then used a proportional-hazard model including centres. FINDINGS: The overall results at 3 years were 57% (95% CI 53-61) for leukaemia-free survival (LFS), 23% (19-27) for relapse incidence (RI), and 26% (22-30) for treatment-related mortality (TRM) with a range for centres of 36-75%, 10-37%, and 8-54%, respectively. Both methods of analysis showed the centre effect to be highly significant for LFS and TRM, but not for RI. Variables associated with a significantly poor outcome were age over 43 years (p=0.01), time from diagnosis to first complete remission longer than 65 days (p=0.02), and centre (p=0.013) for LFS, and age over 43 years (p=0.023), time from first complete remission to transplantation of longer than 93 days (p=0.03), and centre (p=0.001) for TRM. Moreover, different centres had different prognostic criteria for good-risk or bad-risk patients indicating that risk factors do not have the same impact in each individual centre. INTERPRETATION: The outcome of bone-marrow transplantation for acute myeloid leukaemia in first complete remission is influenced by the centre in which the procedure is done, even with adjustment for known prognostic risk factors. Significant prognostic factors vary among centres, which means that the relative risk is not the same in each individual centre. However, centres may treat populations with different risks of as yet unidentified prognostic factors. Experience may partly account for the difference in outcome among centres.
机译:背景:识别和复制良好临床实践的压力越来越大。我们进行了一项研究,以评估欧洲主要中心之间同种异体骨髓移植的预后差异。方法:我们研究了13个中心,包括522例患者(年龄16-55岁),他们在1987年1月1日至1995年12月31日之间进行了30多次骨髓移植,首次完全缓解。我们对先前已知的影响结果的所有因素进行了(全局)多变量分析,并进行了分层分析,该分析最初通过多变量分析在此研究中定义了重要变量,然后使用了包括中心在内的比例风险模型。结果:3年的无白血病生存率(LFS)为57%(95%CI 53-61),复发发生率(RI)为23%(19-27),26%(22-30)治疗相关死亡率(TRM),中心范围分别为36-75%,10-37%和8-54%。两种分析方法均表明,中心效应对LFS和TRM非常重要,而对RI则不然。与明显差的结局相关的变量是年龄超过43岁(p = 0.01),从诊断到首次完全缓解的时间超过65天(p = 0.02),LFS的中枢(p = 0.013)和年龄超过43岁(p = 0.023),从首次完全缓解到移植的时间超过93天(p = 0.03),TRM居中(p = 0.001)。此外,对于高风险或低风险患者,不同的中心对预后的标准也不同,这表明风险因素在每个中心的影响都不相同。解释:首次完全缓解的骨髓移植治疗首次完全缓解的结果受手术过程中心的影响,即使调整了已知的预后危险因素也是如此。各中心的重要预后因素各不相同,这意味着每个中心的相对风险并不相同。但是,中心可能会对尚未确定的预后因素具有不同风险的人群进行治疗。经验可能部分解释了各中心之间结果的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号